Advanced Biomed Inc. (ADVB): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$742.6K

Year ended 2025-06-30

Period ended	EBITDA	Change YoY	Source filing
2025-06-30	-$742.6K	n/a	2026-10-13, From 2024-07-01

EBITDA at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EBITDA	Change YoY
Advanced Biomed Inc. (ADVB)	2025-06-30	-$742.6K	n/a
Aclarion, Inc. (ACON)	2025-12-31	-$6.82M	n/m
Renalytix plc (RNLXY)	2024-06-30	-$29.24M	n/m
CapForce Inc. (CFOR)	2025-12-31	$24.22M	n/m
First Choice Healthcare Solutions, Inc. (FCHS)	2025-12-31	-$2.65M	n/m
American Shared Hospital Services (AMS)	2025-12-31	$2.13M	-36.9%
Exagen Inc. (XGN)	2025-12-31	-$11.97M	n/m
Biodesix Inc (BDSX)	2025-12-31	-$22.20M	n/m
Sera Prognostics, Inc. (SERA)	2025-12-31	-$35.56M	n/m

Compare ADVB, ACON, RNLXY, CFOR side by side · Screen every company in Services-Medical Laboratories ↗